For Immediate Release

Chicago, IL – October 23, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Wal-Mart (WMT), Capital One (COF), Merck (MRK), GlaxoSmithKline (GSK) and Schering Plough (SGP).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Thursday’s AnalystBlog:

New Jobless Claims Up

This long-term unemployment is an insidious problem for the economy. People who are out of work for just a few weeks really don't have to cut back on their consumption that much, especially if they feel confident that they will have a new job in a short time.

People

...

Merck’s (MRK) earnings for the third quarter came in at 90 cents per share, which was ahead of the Zacks Consensus Estimate of 82 cents, driven by continued growth of its key products and strict cost management. The company reported revenues of $6 billion, up 2% from the same period in 2008. Revenue would have higher, but for the unfavorable foreign exchange movement, which affected global sales by 3%. Weaker-than-expected sales of Gardasil were offset by significantly stronger-than-anticipated Singulair revenues. Although the US Food and Drug Administration (FDA) asked for additional precautions regarding the risks associated with the use of Merck’s lead product Singulair (as well as other leukotriene inhibitors), including suicide and depression, the drug recorded an increase of 5% compared to the third quarter of 2008. Gardasil, Merck’s cervical cancer vaccine, recorded yet another quarter of lower sales. The company recorded $311 million in ...

Merck (MRK) recently received U.S. Food and Drug Administration (FDA) approval for the use of its vaccine, Gardasil, for the protection of boys and men aged 9–26 years from genital warts related to human papillomavirus (HPV) types 6 and 11. Originally, Gardasil was approved by the FDA in June 2006, as the first vaccine for cervical cancer, (caused by HPV) for females between 9 to 26 years of age.   Earlier, in September, Gardasil received favorable recommendation from the FDA’s advisory panel. The panel voted 7-1 in favor of the vaccine’s safety and 7-0 (with one abstention) regarding its effectiveness. Apart from the favorable recommendation, the panel members expressed their concern about the lack of long-term data, which would have showed the timeframe of effectiveness of the vaccine.   The final approval of the vaccine follows the results of Merck’s phase III studies of Gardasil conducted over a period

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Friday October 16, 2009

DrStockPick.com Stock Report!

NOK, PWRM, MRK, CSRH, TXN, CVAT, HAL, AQNM

**************************************************************

NOK, Nokia Corp.

NOK is a pioneer in mobile telecommunications and the world’s leading maker of mobile devices.

NOK and Accenture announced the completion of Accenture’s acquisition of Nokia’s Symbian Professional Services, which was initially announced on July 17, 2009. With this transfer, Accenture assumes full ownership of Nokia’s Symbian Professional Services unit responsible for Symbian OS customer engineering and customer support.

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways,

...